EGFR and non-small cell lung carcinoma: A systemic review and meta-analysis studied the genomic alterations and incidences of BMs in advanced NSCLC, and showed that the pooled prevalence of BMs at diagnosis was 28.6%, highest in ALK rearranged patients (34.9%), followed by those with RET translocations (32.2%), KRAS (30.2%), ROS1 (30.1%), and EGFR (29.4%) [28].